{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:46:34Z","timestamp":1794368794094,"version":"4.9.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41401-025-01525-7","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:56:09Z","timestamp":1741686969000},"page":"1958-1973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oral FPR2\/ALX modulators tune myeloid cell activity to ameliorate mucosal inflammation in inflammatory bowel disease"],"prefix":"10.1038","volume":"46","author":[{"given":"Wen-sheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-lin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652\u201364.","journal-title":"N Engl J Med"},{"key":"1525_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"GG Kaplan","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1525_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1525_CR4","first-page":"375","volume":"22","author":"J Mayberry","year":"2013","unstructured":"Mayberry J. The history of 5-ASA compounds and their use in ulcerative colitis-trailblazing discoveries in gastroenterology. J Gastrointestin Liver Dis. 2013;22:375\u20137.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00535-016-1283-0","volume":"52","author":"HC Chan","year":"2017","unstructured":"Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141\u201350.","journal-title":"J Gastroenterol"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ibd\/izaa045","volume":"26","author":"GT Ho","year":"2020","unstructured":"Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of inflammation and gut repair in IBD: translational steps towards complete mucosal healing. Inflamm Bowel Dis. 2020;26:1131\u201343.","journal-title":"Inflamm Bowel Dis"},{"key":"1525_CR7","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Va\u0148\u00e1sek T, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779\u201389.","journal-title":"Lancet"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/1756283X14558193","volume":"8","author":"A Amiot","year":"2015","unstructured":"Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66\u201382.","journal-title":"Therap Adv Gastroenterol"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12876-021-02074-z","volume":"22","author":"J Li","year":"2022","unstructured":"Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, et al. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol. 2022;22:44.","journal-title":"BMC Gastroenterol"},{"key":"1525_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107879","volume":"227","author":"D Panigrahy","year":"2021","unstructured":"Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: An organizing principle in biology and medicine. Pharmacol Ther. 2021;227:107879.","journal-title":"Pharmacol Ther"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92\u2013101.","journal-title":"Nature"},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","volume":"36","author":"M Perretti","year":"2015","unstructured":"Perretti M, Leroy X, Bland EJ, Montero-Melendez T. Resolution pharmacology: opportunities for therapeutic innovation in inflammation. Trends Pharmacol Sci. 2015;36:737\u201355.","journal-title":"Trends Pharmacol Sci"},{"key":"1525_CR13","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1111\/bph.15212","volume":"177","author":"M Perretti","year":"2020","unstructured":"Perretti M, Godson C. Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology. Br J Pharmacol. 2020;177:4595\u2013600.","journal-title":"Br J Pharmacol"},{"key":"1525_CR14","doi-asserted-by":"crossref","unstructured":"Doyle R, Godson C, editors. Chapter 5 - Endogenous antiinflammatory and proresolving lipid mediators in renal disease. United States: Academic Press; 2022. p 55\u201367.","DOI":"10.1016\/B978-0-12-823318-4.00009-3"},{"key":"1525_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1757-3","volume":"21","author":"H Zhang","year":"2017","unstructured":"Zhang H, Lu Y, Sun G, Teng F, Luo N, Jiang J, et al. The common promoter polymorphism rs11666254 downregulates FPR2\/ALX expression and increases risk of sepsis in patients with severe trauma. Crit Care. 2017;21:171.","journal-title":"Crit Care"},{"key":"1525_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S2468-1253(17)30031-6","volume":"2","author":"G Rogler","year":"2017","unstructured":"Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2:521\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1525_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mam.2017.05.001","volume":"58","author":"EP Brennan","year":"2017","unstructured":"Brennan EP, Cacace A, Godson C. Specialized pro-resolving mediators in renal fibrosis. Mol Aspects Med. 2017;58:102\u201313.","journal-title":"Mol Aspects Med"},{"key":"1525_CR18","doi-asserted-by":"crossref","unstructured":"Crocetti L, Vergelli C, Guerrini G, Giovannoni MP, Kirpotina LN, Khlebnikov AI, et al. Pyridinone derivatives as interesting formyl peptide receptor (FPR) agonists for the treatment of rheumatoid arthritis. Molecules. 2021;26:6583.","DOI":"10.3390\/molecules26216583"},{"key":"1525_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14232","volume":"8","author":"CX Qin","year":"2017","unstructured":"Qin CX, May LT, Li R, Cao N, Rosli S, Deo M, et al. Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice. Nat Commun. 2017;8:14232.","journal-title":"Nat Commun"},{"key":"1525_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.intimp.2018.08.011","volume":"63","author":"L Possebon","year":"2018","unstructured":"Possebon L, Costa SS, Souza HR, Azevedo LR, Sant\u2019Ana M, Iyomasa-Pilon MM, et al. Mimetic peptide AC2-26 of annexin A1 as a potential therapeutic agent to treat COPD. Int Immunopharmacol. 2018;63:270\u201381.","journal-title":"Int Immunopharmacol"},{"key":"1525_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejmech.2017.09.023","volume":"141","author":"ML Stama","year":"2017","unstructured":"Stama ML, \u015alusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, et al. Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. Eur J Med Chem. 2017;141:703\u201320.","journal-title":"Eur J Med Chem"},{"key":"1525_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2013.77","volume":"45","author":"SD Kim","year":"2013","unstructured":"Kim SD, Kwon S, Lee SK, Kook M, Lee HY, Song KD, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013;45:e40.","journal-title":"Exp Mol Med"},{"key":"1525_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113167","volume":"213","author":"M Maciuszek","year":"2021","unstructured":"Maciuszek M, Cacace A, Brennan E, Godson C, Chapman TM. Recent advances in the design and development of formyl peptide receptor 2 (FPR2\/ALX) agonists as pro-resolving agents with diverse therapeutic potential. Eur J Med Chem. 2021;213:113167.","journal-title":"Eur J Med Chem"},{"key":"1525_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41401-022-00944-0","volume":"44","author":"WS Yang","year":"2023","unstructured":"Yang WS, Wang JL, Wu W, Wang GF, Yan J, Liu Q, et al. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease. Acta Pharmacol Sin. 2023;44:19\u201331.","journal-title":"Acta Pharmacol Sin"},{"key":"1525_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17933-8","volume":"11","author":"J Duan","year":"2020","unstructured":"Duan J, Shen DD, Zhou XE, Bi P, Liu QF, Tan YX, et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. Nat Commun. 2020;11:4121.","journal-title":"Nat Commun"},{"key":"1525_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/acsptsci.8b00017","volume":"1","author":"YL Liang","year":"2018","unstructured":"Liang YL, Zhao P, Draper-Joyce C, Baltos JA, Glukhova A, Truong TT, et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharmacol Transl Sci. 2018;1:12\u201320.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1525_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14728-9","volume":"11","author":"Y Zhuang","year":"2020","unstructured":"Zhuang Y, Liu H, Edward Zhou X, Kumar Verma R, de Waal PW, Jang W, et al. Structure of formylpeptide receptor 2-G(i) complex reveals insights into ligand recognition and signaling. Nat Commun. 2020;11:885.","journal-title":"Nat Commun"},{"key":"1525_CR28","doi-asserted-by":"crossref","unstructured":"Zhu Y, Lin X, Zong X, Han S, Wang M, Su Y, et al. Structural basis of FPR2 in recognition of A\u03b242 and neuroprotection by humanin. Nat Commun. 2022;13:1775.","DOI":"10.1038\/s41467-022-29361-x"},{"key":"1525_CR29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47:1739\u201349.","journal-title":"J Med Chem"},{"key":"1525_CR30","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1124\/mol.104.004309","volume":"66","author":"M Nanamori","year":"2004","unstructured":"Nanamori M, Cheng X, Mei J, Sang H, Xuan Y, Zhou C, et al. A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004;66:1213\u201322.","journal-title":"Mol Pharmacol"},{"key":"1525_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1124\/mol.107.037564","volume":"72","author":"C Zhou","year":"2007","unstructured":"Zhou C, Zhang S, Nanamori M, Zhang Y, Liu Q, Li N, et al. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007;72:976\u201383.","journal-title":"Mol Pharmacol"},{"key":"1525_CR32","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nprot.2017.044","volume":"12","author":"S Wirtz","year":"2017","unstructured":"Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295\u2013309.","journal-title":"Nat Protoc"},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016;22:1402\u201310.","journal-title":"Nat Med"},{"key":"1525_CR34","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.4049\/jimmunol.1700210","volume":"200","author":"S Bansal","year":"2018","unstructured":"Bansal S, Yajjala VK, Bauer C, Sun K. IL-1 signaling prevents alveolar macrophage depletion during influenza and Streptococcus pneumoniae coinfection. J Immunol. 2018;200:1425\u201333.","journal-title":"J Immunol"},{"key":"1525_CR35","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/cdd.2016.71","volume":"23","author":"Q Yang","year":"2016","unstructured":"Yang Q, Zheng C, Cao J, Cao G, Shou P, Lin L, et al. Spermidine alleviates experimental autoimmune encephalomyelitis through inducing inhibitory macrophages. Cell Death Differ. 2016;23:1850\u201361.","journal-title":"Cell Death Differ"},{"key":"1525_CR36","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/femsre\/fux035","volume":"41","author":"R Mart\u00edn","year":"2017","unstructured":"Mart\u00edn R, Chain F, Miquel S, Motta JP, Vergnolle N, Sokol H, et al. Using murine colitis models to analyze probiotics-host interactions. FEMS Microbiol Rev. 2017;41:S49\u2013S70.","journal-title":"FEMS Microbiol Rev"},{"key":"1525_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378.","journal-title":"Eur Urol"},{"key":"1525_CR38","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.4182","volume":"11","author":"AK Singh","year":"2021","unstructured":"Singh AK, Blanco A, Sinnott R, Knaus UG. Rapid isolation and flow cytometry analysis of murine intestinal immune cells after chemically induced colitis. Bio-protocol. 2021;11:e4182.","journal-title":"Bio-protocol."},{"key":"1525_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-024-00649-0","volume":"10","author":"ZT Cong","year":"2024","unstructured":"Cong ZT, Zhao FH, Li Y, Luo G, Mai YT, Chen XY, et al. Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with G proteins. Cell Discov. 2024;10:18.","journal-title":"Cell Discov"},{"key":"1525_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","volume":"25","author":"JA Ballesteros","year":"1995","unstructured":"Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 1995;25:366\u2013428.","journal-title":"Methods Neurosci"},{"key":"1525_CR41","doi-asserted-by":"crossref","unstructured":"Zhou Q, Yang D, Wu M, Guo Y, Guo W, Zhong L, et al. Common activation mechanism of class A GPCRs. Elife. 2019;8:e50279.","DOI":"10.7554\/eLife.50279"},{"key":"1525_CR42","doi-asserted-by":"crossref","unstructured":"He HQ, Ye RD. The formyl peptide receptors: diversity of ligands and mechanism for recognition. Molecules. 2017;22:455.","DOI":"10.3390\/molecules22030455"},{"key":"1525_CR43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1745-7254.2007.00579.x","volume":"28","author":"J Cui","year":"2007","unstructured":"Cui J, Zhang M, Zhang YQ, Xu ZH. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin. 2007;28:601\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"1525_CR44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.it.2019.01.007","volume":"40","author":"MA Sugimoto","year":"2019","unstructured":"Sugimoto MA, Vago JP, Perretti M, Teixeira MM. Mediators of the resolution of the inflammatory response. Trends Immunol. 2019;40:212\u201327.","journal-title":"Trends Immunol"},{"key":"1525_CR45","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.1096\/fj.201901163R","volume":"33","author":"D Birkl","year":"2019","unstructured":"Birkl D, O\u2019Leary MN, Quiros M, Azcutia V, Schaller M, Reed M, et al. Formyl peptide receptor 2 regulates monocyte recruitment to promote intestinal mucosal wound repair. Faseb J. 2019;33:13632\u201343.","journal-title":"Faseb J"},{"key":"1525_CR46","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/eji.201444988","volume":"45","author":"SH Kim","year":"2015","unstructured":"Kim SH, Yang IY, Kim J, Lee KY, Jang YS. Antimicrobial peptide LL-37 promotes antigen-specific immune responses in mice by enhancing Th17-skewed mucosal and systemic immunities. Eur J Immunol. 2015;45:1402\u201313.","journal-title":"Eur J Immunol"},{"key":"1525_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15009-1","volume":"11","author":"T Chen","year":"2020","unstructured":"Chen T, Xiong M, Zong X, Ge Y, Zhang H, Wang M, et al. Structural basis of ligand binding modes at the human formyl peptide receptor 2. Nat Commun. 2020;11:1208.","journal-title":"Nat Commun"},{"key":"1525_CR48","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41401-020-00523-1","volume":"41","author":"YJ Ge","year":"2020","unstructured":"Ge YJ, Liao QW, Xu YC, Zhao Q, Wu BL, Ye RD. Anti-inflammatory signaling through G protein-coupled receptors. Acta Pharmacol Sin. 2020;41:1531\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"1525_CR49","doi-asserted-by":"publisher","first-page":"18232","DOI":"10.1073\/pnas.1308253110","volume":"110","author":"SN Cooray","year":"2013","unstructured":"Cooray SN, Gobbetti T, Montero-Melendez T, McArthur S, Thompson D, Clark AJ, et al. Ligand-specific conformational change of the G-protein-coupled receptor ALX\/FPR2 determines proresolving functional responses. Proc Natl Acad Sci USA. 2013;110:18232\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1525_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.cytogfr.2006.09.009","volume":"17","author":"I Migeotte","year":"2006","unstructured":"Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006;17:501\u201319.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1525_CR51","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.4049\/jimmunol.1101305","volume":"187","author":"AF Bento","year":"2011","unstructured":"Bento AF, Claudino RF, Dutra RC, Marcon R, Calixto JB. Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. J Immunol. 2011;187:1957\u201369.","journal-title":"J Immunol"},{"key":"1525_CR52","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1158\/1535-7163.MCT-21-0414","volume":"20","author":"T Dong","year":"2021","unstructured":"Dong T, Dave P, Yoo E, Ebright B, Ahluwalia K, Zhou E, et al. NAP1051, a lipoxin A4 biomimetic analog, demonstrates antitumor activity against the tumor microenvironment. Mol Cancer Ther. 2021;20:2384\u201397.","journal-title":"Mol Cancer Ther"},{"key":"1525_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105117","volume":"161","author":"S Zhang","year":"2020","unstructured":"Zhang S, Gong H, Ge Y, Ye RD. Biased allosteric modulation of formyl peptide receptor 2 leads to distinct receptor conformational states for pro- and anti-inflammatory signaling. Pharmacol Res. 2020;161:105117.","journal-title":"Pharmacol Res"},{"key":"1525_CR54","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/aps.2011.4","volume":"32","author":"M He","year":"2011","unstructured":"He M, Cheng N, Gao WW, Zhang M, Zhang YY, Ye RD, et al. Characterization of Quin-C1 for its anti-inflammatory property in a mouse model of bleomycin-induced lung injury. Acta Pharmacol Sin. 2011;32:601\u201310.","journal-title":"Acta Pharmacol Sin"},{"key":"1525_CR55","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202317815","volume":"15","author":"MY Wu","year":"2023","unstructured":"Wu MY, Ge YJ, Wang EJ, Liao QW, Ren ZY, Yu Y, et al. Enhancement of efferocytosis through biased FPR2 signaling attenuates intestinal inflammation. EMBO Mol Med. 2023;15:e17815.","journal-title":"EMBO Mol Med"},{"key":"1525_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1021634","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao F, Gong W, Song J, Shen Z, Cui D. The paradoxical role of MDSCs in inflammatory bowel diseases: from bench to bedside. Front Immunol. 2022;13:1021634.","journal-title":"Front Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01525-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01525-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01525-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:02:40Z","timestamp":1751011360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01525-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01525-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}